** Proteomics International Laboratories PIQ.AX jumps as much as 9.5% to A$0.810, highest since Oct. 11
** Medical technology firm says its OxiDx test - a finger-prick blood test to measure oxidative stress - accurately identifies muscle damage in marathon runners
** PIQ sets sights on H1 CY25 for Australian commercial launch of OxiDx test
** More than 540,000 shares traded, 5x the 30-day avg
** Stock trims YTD losses to 12.3%
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。